A.D. Gafiullina1, Z.A. Afanasyeva2
1Tatarstan Саnсеr Center, Kazan
2Kazan State Medical Academy ― Branch Campus of the FSBEI FPE RMACPE MOH Russia, Kazan
Afanasyeva Z.A. ― D. Med. Sc., professor of the Department of Oncology, Radiology and Palliative Medicine of Kazan State Medical Academy ― Branch Campus of the FSBEI FPE RMACPE MOH Russia, secretary of the Scientific Society of Oncologists of Tatarstan
29 Sibirskiy Trakt, Kazan, Russian Federation, 420029, tel.: (843) 519-26-31, +7-960-053-73-75, e-mail: firstname.lastname@example.org
Abstract. This is an attempt to review the English-language articles covering the study of the relationship of side effects of antitumour agents to the thyroid gland. We concentrate our attention on the consequences of antitumor treatment affecting the endocrine system (including its steroid and non-steroid components) and the outcomes associated with hormone-metabolic shifts, clinical and diagnostic features. As more patients survive longer after the treatment of cancer, clinicians should be familiar with the side effects associated with endocrine disorders and their elimination. There are no known strategies for the prevention of thyroid disease in patients receiving new antineoplastic agents. Although usually, the time of occurrence of side effects caused by this effect is not predictable, it is recommended to closely monitor patients receiving these antitumor drugs. This can contribute to the early diagnosis and treatment of thyroid disorders, allowing to continue treatment of the primary primary cancer, as well as to improve the patient’s quality of life. There are no known strategies for the prevention of thyroid dysfunction and other endocrine glands in patients receiving anticancer drugs.
Кеу words: malignant neoplasm, chemotherapy, targeted therapy, immune therapy, thyroid gland, hypothyroidism, hyperthyroidism, hypophysitis.